TCGA-B6-A0IM-01A-11R-A034-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 129
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.390
- HEDGEHOG_SIGNALING+0.350
- MITOTIC_SPINDLE+0.350
- G2M_CHECKPOINT+0.330
- ANGIOGENESIS+0.300
- ESTROGEN_RESPONSE_EARLY+0.280
- PROTEIN_SECRETION+0.280
- UV_RESPONSE_DN+0.280
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.270
- E2F_TARGETS+0.200
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.390
- INTERFERON_GAMMA_RESPONSE-0.300
- CHOLESTEROL_HOMEOSTASIS-0.270
- KRAS_SIGNALING_DN-0.230
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.220
- OXIDATIVE_PHOSPHORYLATION-0.210
- MYC_TARGETS_V2-0.200
- IL6_JAK_STAT3_SIGNALING-0.170
- FATTY_ACID_METABOLISM-0.160
- INFLAMMATORY_RESPONSE-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AR-A24L-01A-11R-A169-07 | — | B | 0.851 |
| 2 | TCGA-AN-A041-01A-11R-A034-07 | — | B | 0.788 |
| 3 | TCGA-B6-A0WT-01A-11R-A109-07 | — | B | 0.781 |
| 4 | SRR25617938 | — | B | 0.771 |
| 5 | TCGA-AR-A24P-01A-11R-A169-07 | — | A | 0.769 |
| 6 | TCGA-BH-A1ES-01A-11R-A137-07 | — | B | 0.765 |
| 7 | TCGA-DQ-5631-01A-01R-1873-07 | — | — | 0.747 |
| 8 | TCGA-A8-A08O-01A-21R-A056-07 | — | B | 0.740 |
| 9 | TCGA-E9-A226-01A-21R-A157-07 | — | B | 0.728 |
| 10 | TCGA-E2-A15L-01A-11R-A12D-07 | — | B | 0.727 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.390 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.350 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.350 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.330 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.280 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.280 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.280 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.270 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.200 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.190 | Temsirolimus | — uncovered |
| ANDROGEN_RESPONSE | 0.180 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.180 | Cobimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.070 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.070 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.070 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.050 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.040 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.040 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.030 | Temsirolimus | — uncovered |